
Novartis has announced that it will acquire UK-based Ziarco, to add Ziarco’s lead investigational oral treatment for moderate-to-severe eczema to …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

